Table 2.
Overview of prognostic factors for cervical adenocarcinoma and risk factors for ovarian metastases reported in the studies.
| Author | Year | No. of patients | Stage | Rate of ovarian metastases | Variables included in multivariate analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | FIGO stage | Tumor size | Deep stromal invasion | Parametrial invasion | Corpus uteri invasion | Lymph node metastasis | Vaginal invasion | Blood vessel invasion | |||||
| Xie et al. (26) | 2018 | 128 | IA-IIB | 1/113 (0.9%) | * | * | |||||||
| Kasamatsu et al. (9) | 2009 | 123 | IB | 1/87 (1.15%) | * | * | * | ||||||
| IIA | 0 | ||||||||||||
| IIB | 3/22 (13.6%) | ||||||||||||
| Angel et al. (12) | 1992 | 59 | I | 0/41 | * | ||||||||
| Hopkins et al. (22) | 1987 | 24 | I | 0/16 | * | ||||||||
| Chen et al. (7) | 2016 | 194 | IA | 0/9 | * | * # | # | * # | |||||
| IB | 2/100 (2%) | ||||||||||||
| IIA | 2/26 (7.7%) | ||||||||||||
| IIB | 1/18 (5.6%) | ||||||||||||
| Nakanishi et al. (29) | 2000 | 240 | IA | 0/15 | # | # | |||||||
| IB | 7/178 (3.9%) | ||||||||||||
| IIA | 0/11 | ||||||||||||
| Hu et al. (30) | 2013 | 183 | IB | 1/130 (0.8%) | # | # | # | # | |||||
| IIA | 3/39 (7.7%) | ||||||||||||
| IIB | 1/14 (7.1%) | ||||||||||||
| Natsume et al. (17) | 1999 | 62 | IB | 1/31 (3.2%) | # | # | |||||||
| IIA | 1/3 (33.3%) | ||||||||||||
| IIB | 6/28 (21.4%) | ||||||||||||
| Shimada et al. (31) | 2006 | 546 | IB | 14/376 (3.7%) | # | ||||||||
| IIA | 2/38 (5.3%) | ||||||||||||
| IIB | 13/132 (9.8%) | ||||||||||||
| Zhou et al. (32) | 2017 | 312 | IA | 0/9 | # | # | # | ||||||
| IB | 5/217 (2.3%) | ||||||||||||
| IIA | 8/74 (10.8%) | ||||||||||||
| IIB | 1/12 (8.3%) | ||||||||||||
| Yamamoto et al. (16) | 2001 | 89 | IB | 1/50 (2%) | # | ||||||||
| IIA | 0/2 | ||||||||||||
| IIB | 6/37 (16.2%) | ||||||||||||
| Landoni et al. (14) | 2007 | 380 | IA-IIA | 9/380 (2.4%) | # | # | # | ||||||
| Lu et al. (33) | 2016 | 101 | IA | 0/1 | # | ||||||||
| IB | 4/88 (4.6%) | ||||||||||||
| IIA | 1/12 (8.3%) | ||||||||||||
| Toki et al. (11) | 1991 | 36 | IB-IIB | 2/36 (5.6%) | |||||||||
| Tabata et al. (34) | 1987 | 48 | IB | 2/26 (7.7%) | |||||||||
| IIA | 0/2 | ||||||||||||
| IIB | 2/13 (15.4%) | ||||||||||||
| Kjorstad et al. (15) | 1984 | 150 | IB | 2/150 (1.3%) | |||||||||
| Guo et al. (27) | 2018 | 267 | I-II | 13/223 (5.8%) | |||||||||
| Sutton et al. (13) | 1992 | 121 | IB | 2/80 (2.5%) | |||||||||
| Ruengkhachorn et al. (23) | 2016 | 35 | IA | 0/19 | |||||||||
| Total | 3,098 | OM: | IA 0/53 | IB 42/1513 (2.8%) | IIA 17/208 (3.4%) | IIB 30/254 (11.8%) | |||||||
No., number; FIGO, International Federation of Gynecology and Obstetrics.
*
Prognostic factors for cervical adenocarcinoma.
#
Risk factors for ovarian metastases.